{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:52:39Z","timestamp":1785419559986,"version":"3.56.0"},"reference-count":34,"publisher":"Georg Thieme Verlag KG","issue":"03","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>\n            Background\u2003Immune thrombocytopenia (ITP) is characterised by low platelet counts and often leads to bleeding, fatigue, and reduced health-related quality of life.<\/jats:p><jats:p>\n            Methods\u2003This observational, retrospective, population-based study using BIG-PAC\u00ae database included Spanish paediatric and adult patients with primary ITP diagnosed in primary care and hospitals between 2014 and 2020 (median follow-up: 4 years). Epidemiology, baseline\/clinical characteristics, treatment trends, healthcare resources and costs were analysed.<\/jats:p><jats:p>\n            Results\u2003The BIG-PAC\u00ae database contains records of 1,818,588 patients; 170 adults and 27 children with ITP were included in our analysis. ITP prevalence and annual incidence per 100,000 were estimated in 10.8 (2.8 in chronic ITP [cITP] patients) and 1.5 (0.3 in cITP patients), respectively. Epistaxis was the most common bleeding event, followed by genitourinary and gastrointestinal bleeding; &gt;50%\/&gt;\u200975% of ITP\/cITP patients reported fatigue. Chronic patients had lower platelet counts at baseline and required more transfusions. Corticosteroids, immunosuppressants, and thrombopoietin receptor agonists were the most used agents in first-, second- and third-line treatment, respectively. Thirty-five patients, all of them in chronic phase, underwent splenectomy. Patients had on average 13.9, 6.6, and 1.2 visits\/year to primary care, haematology\/internal medicine, and emergency departments, respectively. More than one-fourth of adult patients took on average 16.3 days of sick leave annually. Mean annual total health care costs were \u20ac10,741 (ITP patients) and \u20ac19,809 (cITP patients).<\/jats:p><jats:p>\n            Conclusion\u2003This is the first study to provide an overall perspective on the situation of the Spanish ITP population in terms of epidemiology, treatment trends, health care resources and costs, highlighting unmet patient needs, and direct and indirect costs\/resource use between 2014 and 2020.<\/jats:p>","DOI":"10.1055\/a-2336-1062","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T22:47:52Z","timestamp":1717195672000},"page":"e252-e265","source":"Crossref","is-referenced-by-count":4,"title":["Epidemiology, Treatment Patterns, and Cost Analysis of Immune Thrombocytopenia in Spain between 2014 and 2020: A Population-based Study"],"prefix":"10.1055","volume":"08","author":[{"given":"Tom\u00e1s J.","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hospital Universitario de Burgos, Burgos, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Alperovich","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum AB, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Burillo","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum AB, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Espejo-Saavedra Soler","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum AB, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rebollo-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Atrys Health S.A., Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Atrys Health S.A., Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Justicia","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum AB, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda L.","family":"Lozano","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hospital General Universitario Jos\u00e9 Mar\u00eda Morales Meseguer, Centro Regional de Hemodonaci\u00f3n, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"issue":"09","key":"ref1","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1111\/jth.15366","article-title":"Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology","volume":"19","author":"H Al-Samkari","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.hoc.2013.03.001","article-title":"Immune thrombocytopenia","volume":"27","author":"G Kistangari","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"ref3","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"F Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0039-1683416","article-title":"Epidemiology and clinical manifestations of immune thrombocytopenia","volume":"39","author":"R Kohli","year":"2019","journal-title":"Hamostaseologie"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"4621416","DOI":"10.1155\/2019\/4621416","article-title":"Management of adult patients with primary immune thrombocytopenia (ITP) in clinical practice: a consensus approach of the Spanish ITP Expert Group","volume":"2019","author":"M E Mingot-Castellano","year":"2019","journal-title":"Adv Hematol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"103820","DOI":"10.1016\/j.ebiom.2022.103820","article-title":"Recent advances in the mechanisms and treatment of immune thrombocytopenia","volume":"76","author":"D Provan","year":"2022","journal-title":"EBioMedicine"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/ajh.24463","article-title":"Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease","volume":"91","author":"F Efficace","year":"2016","journal-title":"Am J Hematol"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.26036","article-title":"Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): impact of ITP on health-related quality of life","volume":"96","author":"N Cooper","year":"2021","journal-title":"Am J Hematol"},{"issue":"21","key":"ref9","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-03-754119","article-title":"Clinical updates in adult immune thrombocytopenia","volume":"129","author":"M P Lambert","year":"2017","journal-title":"Blood"},{"issue":"22","key":"ref11","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"D Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/j.1538-7836.2006.02147.x","article-title":"Prevalence of immune thrombocytopenia: analyses of administrative data","volume":"4","author":"J B Segal","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.tmrv.2022.08.003","article-title":"Changing paradigms in ITP management: newer tools for an old disease","volume":"36","author":"D Jiang","year":"2022","journal-title":"Transfus Med Rev"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1007\/s12325-022-02133-1","article-title":"Proposal for a new protocol for the management of immune thrombocytopenia (ITP)","volume":"39","author":"T J Gonz\u00e1lez-L\u00f3pez","year":"2022","journal-title":"Adv Ther"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2147\/JBM.S259101","article-title":"Management of adult patients with immune thrombocytopenia (ITP): a review on current guidance and experience from clinical practice","volume":"12","author":"F Song","year":"2021","journal-title":"J Blood Med"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3324\/haematol.2019.229179","article-title":"The child with immune thrombocytopenia: to treat or not to treat, is that still the question?","volume":"104","author":"N Cooper","year":"2019","journal-title":"Haematologica"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1080\/16078454.2021.1992945","article-title":"Characterization and treatment of immune thrombocytopenia in Europe: a qualitative observational study","volume":"26","author":"E A Pogna","year":"2021","journal-title":"Hematology"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/09537104.2019.1635687","article-title":"The incidence and clinical burden of immune thrombocytopenia in pediatric patients in the United States","volume":"31","author":"J Shaw","year":"2020","journal-title":"Platelets"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/13696998.2019.1669329","article-title":"Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis","volume":"23","author":"D Weycker","year":"2020","journal-title":"J Med Econ"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"S374","DOI":"10.1016\/j.jval.2019.09.1764","article-title":"PMU146 validation and representativeness of the Spanish Big-Pac database: integrated computerized medical records for research into epidemiology, medicines and health resource use (real word evidence)","volume":"22","author":"A Sicras-Mainar","year":"2019","journal-title":"Value Health"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1182\/asheducation-2016.1.698","article-title":"Second-line therapies in immune thrombocytopenia","volume":"2016","author":"R F Grace","year":"2016","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"09","key":"ref25","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ajh.23262","article-title":"Prevalence of primary immune thrombocytopenia in Oklahoma","volume":"87","author":"D R Terrell","year":"2012","journal-title":"Am J Hematol"},{"issue":"22","key":"ref27","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood-2012-12-466375","article-title":"Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS)","volume":"121","author":"C E Neunert","year":"2013","journal-title":"Blood"},{"issue":"08","key":"ref28","first-page":"484","article-title":"Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study","volume":"22","author":"J Palau","year":"2017","journal-title":"Hematology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000442769","article-title":"Outpatient management of patients with immune thrombocytopenia (ITP) by hematologists 1995-2014","volume":"39","author":"R Weide","year":"2016","journal-title":"Oncol Res Treat"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"e0198184","DOI":"10.1371\/journal.pone.0198184","article-title":"Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: results from a long-term observation in clinical practice","volume":"13","author":"F Depr\u00e9","year":"2018","journal-title":"PLoS ONE"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"127.e1","DOI":"10.1016\/j.anpedi.2019.04.014","article-title":"Protocolo de estudio y tratamiento de la trombocitopenia inmune primaria: PTI-2018","volume":"91","author":"E Monteagudo","year":"2019","journal-title":"An Pediatr"},{"issue":"06","key":"ref32","doi-asserted-by":"crossref","first-page":"e12592","DOI":"10.1002\/rth2.12592","article-title":"Corticosteroid overuse in adults with immune thrombocytopenia: cause for concern","volume":"5","author":"A Cuker","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"ref35","volume-title":"Directrices de diagn\u00f3stico, tratamiento y seguimiento de la PTI: Documento de Consenso","author":"Sociedad Espa\u00f1ola de Hematolog\u00eda y H","year":"2011"},{"issue":"23","key":"ref36","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"C Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"07","key":"ref37","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00277-016-2665-3","article-title":"Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines","volume":"95","author":"M L Lozano","year":"2016","journal-title":"Ann Hematol"},{"issue":"06","key":"ref38","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/ajh.25092","article-title":"Transitioning patients with immune thrombocytopenia to second-line therapy: challenges and best practices","volume":"93","author":"A Cuker","year":"2018","journal-title":"Am J Hematol"},{"issue":"02","key":"ref39","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ajh.20992","article-title":"Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura","volume":"83","author":"R McMillan","year":"2008","journal-title":"Am J Hematol"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1186\/s12913-020-05828-9","article-title":"Costs and healthcare utilisation of patients with heart failure in Spain","volume":"20","author":"C Escobar","year":"2020","journal-title":"BMC Health Serv Res"},{"issue":"05","key":"ref41","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s13300-021-01039-5","article-title":"Glucagon-like peptide 1 receptor agonists in type 2 diabetes mellitus: data from a real-world study in Spain","volume":"12","author":"K Norrbacka","year":"2021","journal-title":"Diabetes Ther"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2336-1062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:48:32Z","timestamp":1730807312000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2336-1062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":34,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2024,7,8]]},"published-print":{"date-parts":[[2024,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2336-1062","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"value":"2512-9465","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,31]]},"published":{"date-parts":[[2024,5,31]]}}}